1Whitehouse C, Solamon E. Current status of molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening [ J 1. Gynecol Oncol, 2003, 88( 1 Pt 2) :S152-S157.
3Stem A, Laughlin GA, Bergstrom J, et al. The sex-specific association of serum ostcoprotegerin and receptor activator of nuclear factor kappa B legend with bone mineral density in older aduhs, the Rancho Bemardo study [ J ]. Eur J Endcrion, 2007,156 (5) : 555-562.
7Alvarez L, Peris P, Guanabens N, et al. Serum osteoprotegerin and its ligand in Peget's disease of bone re- lationship to disease activity and effect of treatment with bisphosphonates [ J ]. Arthritis Rheum, 2003,48 ( 3 ) : 824-828.
8Anand DV, lahiri A, Lin E, et al. Therelationship between plsam osteopro- tegerin levels and coronary artey clasification in complicated type diabitic subjects [ J ]. J Am Coil Car- diol, 2006,47(9) : 1850-1857.
9Kovacs E J, MesSinghan KA, Infuence of alcohol and gender on immupe re- sponse [ J ]. Alcohol Res Health, 2002,26(4) :257-263.
10Parler DK, Menon U, Mcintosh M, et al.Factors influencing serum CA125II levels in healthy postmenopausal women [ J ]. Cancer Epidemiol Bio- markers Prey, 2001,10(5) : 489-493.
7Ryan JL, Carroll JK, Ryan EP, et al. Mechanisms of cancer-related fatigue[ J ]. Oncologist, 2007,12 ( 1 ) :22-34.
8Stem A, Laughlin GA, Bergstrom J, et al. The sex - specificassociation of serum ostcoprotegerin and receptor activator of nuclear factor kappa B legend with bone mineral density in older adults:the Rancho Bemardo study[ J]. Eur J Endocrinol, 2007,156 ( 5 ) : 555-562.
9Alvarez L, Peris P, Guanabens N, et al. Serum osteoprotegerin and its ligand in Peget's disease of bone:relationship to disease activity and effect of treatment with bisphosphonates[ J ]. Arthritis Rheum,2003,48 : 824-828.
10Anand DV, lahiri A, Lim E, et al. The relationgship between plasma osteoprotegerin levels and coronary artery calcificaton in complicated type diabetic subjects [ J ]. J Am Coll Cardiol,2006,47(9) : 1850-1857.
